title: Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.
abstract: BACKGROUND
  Recent reports of fatal ticlopidine-induced blood dyscrasias have led many interventional cardiologists to administer clopidogrel instead of ticlopidine for coronary stenting. Most studies have demonstrated similar outcomes and a more favourable safety profile supporting this change in practice patterns.
  
  
  OBJECTIVE
  To assess the clinical outcomes in patients who received clopidogrel rather than ticlopidine after coronary stenting.
  
  
  METHODS
  Between June 1996 and December 1998, 652 patients received a clopidogrel-based periprocedural regimen (300 mg loading dose followed by 75 mg daily in addition to acetylsalicylic acid 325 mg daily) and 1717 patients received a ticlopidine-based regimen (500 mg loading dose followed by 250 mg bid in addition to acetylsalicylic acid 325 mg daily). In-hospital and 30-day outcomes were assessed in the two groups.
  
  
  RESULTS
  At 30 days, unadjusted mortality was 0.3% in the clopidogrel group versus 1.5% in the ticlopidine group, and myocardial infarction (MI) was also reduced in the clopidogrel group (4.0% versus 6.5%). No difference was found in the rate of repeat revascularization (1.4% versus 1.2%). The combination of death/MI/repeat revascularization at 30 days was reduced by 32%, an absolute difference of 2.9% (6.2% versus 9.1%). On multivariate analysis, clopidogrel was found to be an independent predictor of freedom from nonfatal MI (odds ratio [OR] 0.64, 95% CI 0.41 to 0.99, P=0.04), the composite of death or MI (OR 0.62, 95% CI 0.40 to 0.95, P=0.03) and the composite of death/MI/revascularization (OR 0.69, 95% CI 0.48 to 1.00, P=0.05).
  
  
  CONCLUSIONS
  After coronary stenting, in a large, nonrandomized, consecutive patient experience, clopidogrel appears to be associated with more favourable clinical outcomes than ticlopidine, without increasing the risk of bleeding or peripheral vascular complications.
authors.affiliation: Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, USA. philippe.lallier@sympatico.ca
authors.forename: Philippe L
authors.initials: PL
authors.lastname: L'Allier
authors.forename: Herbert D
authors.initials: HD
authors.lastname: Aronow
authors.forename: Fernando A
authors.initials: FA
authors.lastname: Cura
authors.forename: Deepak L
authors.initials: DL
authors.lastname: Bhatt
authors.forename: Abdulhay
authors.initials: A
authors.lastname: Albirini
authors.forename: Jakob P
authors.initials: JP
authors.lastname: Schneider
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Topol
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Ellis
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D002423:Cause of Death; D000077144:Clopidogrel; D023921:Coronary Stenosis / Q000401:mortality / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011292:Premedication; D011358:Product Surveillance, Postmarketing; D012189:Retrospective Studies; D015607:Stents; D016019:Survival Analysis; D013988:Ticlopidine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin